Everand Logo

Welcome to Everand!

  • STAT

    Opinion: STAT+: The problem with potential changes to the biosimilar regulatory framework

    There is no evidence to suggest that the current regulatory framework inhibits biosimilar uptake.
    by Leah Christl Sep 26, 2023 1 minute
    Source: JUAN MABROMATA/AFP via Getty Images

    Biosimilars are no longer a new and untested class of medicines. Today, they provide critical treatment options across multiple therapeutic areas. have come to market offering the potential to increase patient choice and cost savings. And according to the 2023 analysis from , biosimilars are expected to generate $181 billion in savings for the U.S. health care system over the next five years.

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min read
    STAT+: Brain Biopsies On ‘Vulnerable’ Patients At Mount Sinai Set Off Alarm Bells At FDA, Documents Show
    A STAT Investigation: Brain biopsies on "vulnerable" patients at Mount Sinai set off alarm bells at FDA, documents show.
    STAT1 min read
    USDA Faulted For Disclosing Scant Information About Outbreaks Of H5N1 Avian Flu In Cattle
    With 28 herds in eight states infected with H5N1 bird flu, scientists are calling on the U.S. to release more data to help them assess the risk.
    STAT1 min read
    Opinion: STAT+: How AI Can Help Satisfy FDA’s Drug, Device Diversity Requirements
    To meet the Food and Drug Omnibus Reform Act, companies must rethink their current clinical trial strategies. Including AI and machine learning approaches can help.

    Related Books & Audiobooks